The above findings suggest that all these products are able to modulate endogenous mitochondrial pathways such as the anti-apoptotic protein Bcl-2 in order to achieve the treatment of CRC, and such drugs may be potential candidates for the treatment of CRC in the future. Here, BCL2 is linked to colorectal carcinoma.